Successful Management of Tumor Lysis Syndrome Following Enfortumab Vedotin Plus Pembrolizumab Therapy in Metastatic Urothelial Carcinoma: A Case Report

ABSTRACT Introduction Enfortumab vedotin plus pembrolizumab (EV + P) shows high efficacy in metastatic urothelial carcinoma (mUC), potentially increasing tumor lysis syndrome (TLS) risk. Case Presentation A 64‐year‐old man with mUC underwent surgery and adjuvant nivolumab after neoadjuvant chemother...

詳細記述

書誌詳細

主要な著者:	Daigo Takemori, Ryu Shigehisa, Sho Shimasaki, Erika Yamashita, Yoshitaka Kurano, Kaya Atagi, Yuhi Ota, Shinkuro Yamamoto, Hiroto Osakabe, Tomoya Nao, Tsutomu Shimamoto, Hideo Fukuhara, Nobutaka Shimizu, Satoshi Fukata, Shingo Ashida, Keiji Inoue
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2025-09-01
シリーズ:	IJU Case Reports
主題:	enfortumab vedotin metastatic urothelial carcinoma pembrolizumab successful management tumor lysis syndrome
オンライン･アクセス:	https://doi.org/10.1002/iju5.70069
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!